NEW YORK, Sept. 1, 2020 /PRNewswire/ --
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]
MVC Capital, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MVC Capital, Inc. in connection with the proposed acquisition of the company by Barings BDC, Inc. ("BBDC"). Under the terms of the acquisition agreement, MVC shareholders will receive 0.94024 shares of BBDC common stock and $0.39492 in cash for each share of MVC common stock that they own, representing implied per-share merger consideration of approximately $8.05 based upon BBDC's August 31, 2020 closing price of $8.14. If you own MVC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/mvc-capital-inc/
Arya Sciences Acquisition Corp II (NASDAQ: ARYBU)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp II (NASDAQ: ARYBU) in connection with the company's proposed merger with privately-held biopharmaceutical company Cerevel Therapeutics, Inc. ("Cerevel"). Under the terms of the merger agreement, ARYBU will fold into Cerevel and cease to exist, forming one publicly-traded entity with existing Cerevel investors and new PIPE investors. Cerevel's management team will continue to lead the combined company, which will trade on the Nasdaq stock exchange under the ticker CERE. At close of the transaction, ARYBU shareholders will only retain a maximum of 11.73% ownership of the combined company. If you own ARYBU shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/arya-sciences-acquisition-corp-ii/
SOURCE WeissLaw LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC13090&Transmission_Id=202009011911PR_NEWS_USPR_____DC13090&DateId=20200901)
Share this article